Life, liberty, and the pursuit of protons: An evidence-based review of the role of particle therapy in the treatment of prostate cancer

Cancer Journal

Volumn 15, Issue 4, 2009, Pages 312-318

  Efstathiou, Jason A ^a   Trofimov, Alexei V ^a   Zietman, Anthony L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dose escalation; Intensity modulated radiation therapy; Prostate cancer; Proton beam therapy; Toxicity

Indexed keywords

CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HUMAN; IN VIVO STUDY; INTENSITY MODULATED RADIATION THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION SAFETY; REVIEW;

DOSE-RESPONSE RELATIONSHIP, RADIATION; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PARTICLE SIZE; PROSTATE; PROSTATIC NEOPLASMS; PROTONS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 69549092039     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181b14ec0     Document Type: Review

References (53)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
2. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 Pt 2):S14-19.
3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)
4. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67-74. (Pubitemid 350251041)
5. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475-487.
6. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990-1996. (Pubitemid 46622106)
7. Wilson RR. Radiologic uses of fast protons. Radiology. 1946;47:487.
8. Gragoudas ES, Lane AM, Munzenrider J, et al. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002;100:43-48, discussion 8-9. (Pubitemid 37039354)
9. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999;175(suppl 2):57-63. (Pubitemid 29533454)
10. MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma; initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71:979-986.
11. Zhang X, Dong L, Lee AK, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007;67:620-629. (Pubitemid 46108332)
12. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69:444-453. (Pubitemid 47380086)
13. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:744-751. (Pubitemid 351199706)
14. Mayahara H, Murakami M, Kagawa K, et al. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience. Int J Radiat Oncol Biol Phys. 2007;69:434-443. (Pubitemid 47380084)
15. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1-7.
16. Schneider U, Lomax A, Besserer J, et al. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:892-897. (Pubitemid 46818764)
17. Wroe A, Rosenfeld A, Schulte R. Out-of-field dose equivalents delivered by proton therapy of prostate cancer. Med Phys. 2007;34:3449-3456. (Pubitemid 47339741)
18. Paganetti H, Bortfeld T, Delaney TF. Neutron dose in proton radiation therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). Int J Radiat Oncol Biol Phys. 2006;66:1594-1595, author reply 5. (Pubitemid 44778947)
19. Zacharatou Jarlskog C, Lee C, Bolch WE, et al. Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms. Phys Med Biol. 2008;53:693-717.
20. Miralbell R, Lomax A, Cella L, et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54:824-829.
21. Shipley WU, Tepper JE, Prout GR Jr, et al. Proton radiation as boost therapy for localized prostatic carcinoma. JAMA. 1979;241:1912-1915.
22. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3-12.
23. Slater JD, Rossi CJ Jr, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59:348-352. (Pubitemid 38622585)
24. Talcott JA, Slater JD, Zietman AL, et al. Long-term quality of life after conventional-dose versus high-dose radiation for prostate cancer: results from a randomized trial (PROG-9509). J Clin Oncol. 2008;26(15S):264s.
25. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
26. Zietman AL, Bae K, Coen JJ, et al. A prospective phase I/II study using proton beam radiation to deliver 82 GyE to men with localized prostate cancer: preliminary results of ACR 0312. In: American Society of Therapeutic Radiology and Oncology. Boston: 2008:S77.
27. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007;25:3603-3608. (Pubitemid 47372597)
28. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
29. Andriole GL, Grubb RL III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
30. Safai S, Bortfeld T, Engelsman M. Comparison between the lateral penumbra of a collimated double-scattered beam and uncollimated scanning beam in proton radiotherapy. Phys Med Biol. 2008;53:1729-1750.
31. Lomax AJ, Pedroni E, Rutz H, et al. The clinical potential of intensity modulated proton therapy. Z Med Phys. 2004;14:147-152. (Pubitemid 39221029)
32. Weber DC, Lomax AJ, Rutz HP, et al. Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol. 2004;71:251-258.
33. Weber DC, Trofimov AV, Delaney TF, et al. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys. 2004;58:1596-1606.
34. Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005;63:401-409.
35. Lomax AJ, Boehringer T, Coray A, et al. Intensity modulated proton therapy: a clinical example. Med Phys. 2001;28:317-324. (Pubitemid 32231687)
36. Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys. 2007;67:497-504. (Pubitemid 46108302)
37. Rutz HP, Weber DC, Sugahara S, et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int J Radiat Oncol Biol Phys. 2007;67:512-520. (Pubitemid 46108303)
38. Unkelbach J, Chan TC, Bortfeld T. Accounting for range uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol. 2007;52:2755-2773. (Pubitemid 46705280)
39. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095-1101. (Pubitemid 29144800)
40. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021-1031. (Pubitemid 32594841)
41. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072-1083.
42. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132-6138. (Pubitemid 46300231)
43. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099-1105.
44. Mouraviev V, Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906-910. (Pubitemid 47257670)
45. John SS, Zietman AL, Shipley WU, et al. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys. 2008;71(1 suppl):S43-S47.
46. Rajesh A, Coakley FV, Kurhanewicz J. 3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol. 2007;62:921-929. (Pubitemid 47317139)
47. Nederveen AJ, van der Heide UA, Hofman P, et al. Partial boosting of prostate tumours. Radiother Oncol. 2001;61:117-126.
48. Pickett B, Vigneault E, Kurhanewicz J, et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44:921-929. (Pubitemid 29284143)
49. Bos LJ, Damen EM, de Boer RW, et al. Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys. 2002;52:254-265.
50. Parodi K, Paganetti H, Shih HA, et al. Patient study of in vivo verification of beam delivery and range, using positron emission tomography and computed tomography imaging after proton therapy. Int J Radiat Oncol Biol Phys. 2007;68:920-934. (Pubitemid 46818759)
51. Russell KJ, Caplan RJ, Laramore GE, et al. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Radiat Oncol Biol Phys. 1994;28:47-54.
52. Forman JD, Duclos M, Sharma R, et al. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Int J Radiat Oncol Biol Phys. 1996;35:259-266. (Pubitemid 26158746)
53. Ishikawa H, Tsuji H, Kamada T, et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 2006;81:57-64. (Pubitemid 44512056)